PMID- 26534766 OWN - NLM STAT- MEDLINE DCOM- 20161213 LR - 20220408 IS - 1523-5866 (Electronic) IS - 1522-8517 (Print) IS - 1522-8517 (Linking) VI - 18 IP - 3 DP - 2016 Mar TI - Nuclear factor-kappaB in glioblastoma: insights into regulators and targeted therapy. PG - 329-39 LID - 10.1093/neuonc/nov265 [doi] AB - Nuclear factor-kappaB (NF-kappaB) is a ubiquitous transcription factor that regulates multiple aspects of cancer formation, growth, and treatment response. Glioblastoma (GBM), the most common primary malignant tumor of the central nervous system, is characterized by molecular heterogeneity, resistance to therapy, and high NF-kappaB activity. In this review, we examine the mechanisms by which oncogenic pathways active in GBM impinge on the NF-kappaB system, discuss the role of NF-kappaB signaling in regulating the phenotypic properties that promote GBM and, finally, review the components of the NF-kappaB pathway that have been targeted for treatment in both preclinical studies and clinical trials. While a direct role for NF-kappaB in gliomagenesis has not been reported, the importance of this transcription factor in the overall malignant phenotype suggests that more rational and specific targeting of NF-kappaB-dependent pathways can make a significant contribution to the management of GBM. CI - (c) The Author(s) 2015. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. FAU - Cahill, Kirk E AU - Cahill KE AD - Section of Neurosurgery, Department of Surgery, University of Chicago, Chicago, Illinois. FAU - Morshed, Ramin A AU - Morshed RA AD - Section of Neurosurgery, Department of Surgery, University of Chicago, Chicago, Illinois. FAU - Yamini, Bakhtiar AU - Yamini B AD - Section of Neurosurgery, Department of Surgery, University of Chicago, Chicago, Illinois. LA - eng GR - R01CA136937/CA/NCI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Review DEP - 20151102 PL - England TA - Neuro Oncol JT - Neuro-oncology JID - 100887420 RN - 0 (NF-kappa B) SB - IM MH - Animals MH - Brain Neoplasms/*drug therapy/pathology MH - Cell Proliferation/*drug effects MH - Drug Resistance, Neoplasm/drug effects MH - Gene Expression Regulation, Neoplastic/*drug effects MH - Glioblastoma/*drug therapy/pathology MH - Humans MH - NF-kappa B/*drug effects/*metabolism PMC - PMC4767244 OTO - NOTNLM OT - NF-kappaB OT - glioblastoma OT - glioma OT - inhibitor EDAT- 2015/11/05 06:00 MHDA- 2016/12/15 06:00 PMCR- 2017/03/01 CRDT- 2015/11/05 06:00 PHST- 2015/07/09 00:00 [received] PHST- 2015/09/24 00:00 [accepted] PHST- 2017/03/01 00:00 [pmc-release] PHST- 2015/11/05 06:00 [entrez] PHST- 2015/11/05 06:00 [pubmed] PHST- 2016/12/15 06:00 [medline] AID - nov265 [pii] AID - 10.1093/neuonc/nov265 [doi] PST - ppublish SO - Neuro Oncol. 2016 Mar;18(3):329-39. doi: 10.1093/neuonc/nov265. Epub 2015 Nov 2.